Developmental Research Program

发展研究计划

• 批准号: 10494111
• 负责人: KEVIN M. SHANNON
• 金额: $ 9.39万
• 依托单位: INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-09-01 至 2026-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10494111
• 关键词: Acceleration; Address; Advanced Malignant Neoplasm; Applications Grants; Area; Basic Science; California; Cancer Center; Clinical; Clinical Sciences; Collaborations; Communities; Country; Data; Department of Defense; Development; Diagnosis; Discipline; Disease; Early treatment; Evaluation; Funding; Funding Agency; Goals; Health Sciences; Human; Human Development; Indiana; Institution; Malignant Neoplasms; Memorial Sloan-Kettering Cancer Center; Mission; NF1 gene; NF1 mutation; National Cancer Institute; Neurofibromatoses; Pediatric Hospitals; Pediatric Oncology; Philadelphia; Pilot Projects; Population Sciences; Predisposition; Process; Research; Research Activity; Research Personnel; Research Project Grants; Resources; San Francisco; Scientist; Senior Scientist; Sex Orientation; Signal Transduction; Syndrome; Talents; Techniques; Texas; Therapeutic; Translational Research; Tumor stage; Underrepresented Minority; Underrepresented Populations; United States National Institutes of Health; Universities; Work; anticancer research; base; career; disability; effective therapy; expectation; faculty support; high reward; high risk; hyperactive Ras; improved; innovation; minority investigator; neoplasm therapy; professor; programs; racial and ethnic; recruit; translational cancer research; translational study; tumor

ABSTRACT – DEVELOPMENTAL REARCH PROGRAM The DHART SPORE Developmental Research Program (DRP) will support innovative pilot projects to advance the diagnosis and treatment of early stage tumors and advanced cancers characterized by germline and somatic NF1 mutations. The DRP will accomplish this goal by supporting rigorous translational research in the areas of population science, therapeutics, and mechanisms of disease. We expect that many established investigators will utilize DRP support to launch new research endeavors and to generate preliminary data in NF1 and RASopathy-associated cancers leading to successful grant applications to the NIH, the Department of Defense NF Research Program, and other funding agencies. The ultimate goal of the DRP is to advance high level research activities related to NF1-associated tumors, which we will achieve by recruiting and supporting established investigators developing a new research theme in the field of NF1-related cancers. The translational studies supported by the DRP also have the potential to replace SPORE projects that have been completed or are not progressing satisfactorily toward achieving their objectives. This SPORE also includes a Career Enhancement Program (CEP) for young investigators, which is described in a separate section of this application. The institutions participating in the DHART SPORE renewal have committed a total of $1.65 million to support the Developmental Programs of the DHART SPORE (inclusive of the DRP and CEP). Investigators from any DHART SPORE center can apply for DRP funds. In addition, we actively solicit applications from non-SPORE investigators and institutions. The specific aims of the DRP are: (1) to fund promising projects in order to generate preliminary data for grant applications to the NIH or other federal funding agencies. The DRP emphasizes supporting the recruitment of investigators from historically disenfranchised racial, ethnic, sexual orientation and disability groups that are under-represented in health sciences, hereafter termed underrepresented minority (URM) investigators ; (2) to support the development of new techniques and resources that can be applied to advance translational research to improve the treatment of NF1-associated tumors; (3) to expand the scope of research in NF1, including funding high risk/high reward projects; and, (4) to recruit talented investigators into NF1 research as it relates to cancer, and to promote new collaborations in this field across a range of investigators and disciplines. The DRP will provide evaluation, funding, and oversight for pilot projects. Each project will receive a minimum of $50,000 with a maximum of $75,000 per year, with the potential for a single renewal. Applications for DRP support (including requests for a second year of funding) will be evaluated through a competitive process with review by a Developmental Programs Steering Committee (DPSC) comprised of senior scientists participating in this SPORE and oversight and guidance from the External and Internal Advisory Boards.

摘要-医疗保健 该DHART孢子发展研究计划（DRP）将支持创新试点项目，以推进 早期肿瘤和晚期癌症的诊断和治疗， 体细胞NF 1突变。DRP将通过支持严格的翻译研究来实现这一目标， 人口科学、治疗学和疾病机制领域。我们预计许多已建立的 研究人员将利用DRP支持开展新的研究工作，并生成初步数据， NF 1和RASopathy相关的癌症导致成功的拨款申请到美国国立卫生研究院，该部 国防NF研究计划和其他资助机构。DRP的最终目标是推进 与NF 1相关肿瘤相关的高水平研究活动，我们将通过招募和 支持已建立的研究人员在NF 1相关癌症领域开发新的研究主题。的 由DRP支持的转化研究也有可能取代那些已经被 已完成或在实现其目标方面进展不令人满意。此SPORE还包括一个 针对年轻研究者的职业提升计划（CEP），在本报告的单独章节中进行了描述。 应用程序.参与DHART SPORE更新的机构共承诺1.65美元 100万美元用于支持DHART SPORE的发展计划（包括DRP和CEP）。 来自任何DHART SPORE中心的研究人员都可以申请DRP资金。此外，我们积极征求 来自非SPORE研究者和机构的申请。DRP的具体目标是：（1）资助 有前途的项目，以产生初步数据，资助申请到美国国立卫生研究院或其他联邦 供资机构。DRP强调支持从历史上招募调查员 被剥夺权利的种族、族裔、性取向和残疾群体在卫生保健方面的代表性不足 科学，以下称为代表性不足的少数民族（URM）研究人员;（2）支持发展 新的技术和资源，可用于推进转化研究，以改善治疗 （3）扩大NF 1的研究范围，包括资助高风险/高回报的研究 项目;以及，（4）招募有才华的研究人员进入NF 1研究，因为它与癌症有关，并促进新的 在这一领域的合作，在一系列的调查和学科。DRP将提供评估， 对试点项目的资助和监督。每个项目将获得最低5万美元，最高 每年75 000美元，有可能一次续约。DRP支持申请（包括申请 第二年的资金）将通过竞争过程进行评估，并由发展 项目指导委员会（DPSC）由参与该SPORE的高级科学家组成， 外部和内部咨询委员会的监督和指导。